|
|
|
LifeScienceHistory.com - Check us out on Instagram
Take Your Next Career Step with Lundback
New York Life Science Industry Directory
Banner Advertising
Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and
delayed by COVID-19, to be launched in 2023 replacing New YorkLifeScience.com. Regrettably, we are working with reduced
staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved
directory upon the launch of the new site. We apologize for the inconvenience.
NeuroproteXeon, Inc.
| | | Phone: | (716) 332-7200 | Fax: | (716) 242-8940 | Year Established: | 2015 | Main Contact: | Matt Napoletano, COO | | Other Contacts: | Bill Burns, CEO
| |
| Company Description | NeuroproteXeon (NPXE) is a late clinical-stage pharmaceutical and medical device company developing the proprietary use of xenon gas, delivered via a patented inhalation device, to protect against brain cell death following acute neurologic injury. NPXE is currently preparing for a Phase III Clinical Trial in Out of Hospital Cardiac Arrest (OHCA) following a publication of positive Phase II Clinical Trial results in JAMA, March 2016. | |
|
|
|
|
|